Success examples
Second-Generation Antimitotics in Cancer Clinical Trials

Novais P., Silva P. M. A., Amorim I., Bousbaa H.

Pharmaceutics 2021, 13(7), 1011.

Aurora B inhibitor
DOI
Success examples
Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains

Nomura T. K., Heishima K., Sugito N., Sugawara R., Ueda H., Yukihiro A., Honda R.

Cell Chem Biol 2021, S2451-9456(21)00206-3.

KRAS switch I/II pocket inhibitor
DOI
PUBMED
Success examples
Fatty acid synthesis is required for breast cancer brain metastasis

Ferraro G. B., Ali A., Luengo A., Kodack D. P., Deik A., Abbott K. L., Bezwada D., Blanc L., Prideaux B., Jin X., Possada J. M., Chen J., Chin C. R., Amoozgar Z., Ferreira R., Chen I. X., Naxerova K., Ng C., Westermark A. M., Duquette M., Roberge S., Lindeman N. I., Lyssiotis C. A., Nielsen J., Housman D. E., Duda D. G., Brachtel E., Golub T. R., Cantley L. C., Asara J. M., Davidson S. M., Fukumura D., Dartois V. A., Clish C. B., Jain R. K., Vander Heiden M. G.

Nature Cancer 2021.

FAS inhibitor
DOI
Success examples
Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors

Buckley B. J., Kumar A., Aboelela A., Bujaroski R. S., Li X., Majed H., Fliegel L., Ranson M., Kelso M. J.

Int. J. Mol. Sci. 2021, 22(6), 2999.

NHE1 inhibitor
DOI
Success examples
Acute BAF perturbation causes immediate changes in chromatin accessibility

Schick S., Grosche S., Kohl K. E., Drpic D., Jaeger M. G., Marella N. C., Imrichova H., Lin J-M. G., Hofstätter G., Schuster M., Rendeiro A. F., Koren A., Petronczki M., Bock C., Müller A. C., Winter G. E., Kubicek S.

Nat Genet 2021, 53(3):269-278.

SMARCA2/4 PROTAC
DOI
PUBMED
Success examples
Recent developments in ligands and chemical probes targeting solute carrier transporters

Casiraghi A., Bensimon A., Superti-Furga G.

Curr Opin Chem Biol 2021, 62:53-63.

SLC13A5 Inhibitor
DOI
PUBMED